Skip to main content

Fewer Incidents Between Youth And Police Following Canadian Legalization

An area of top concern for both cannabis supporters and opponents alike is youth safety. Of course, what motivates each side’s concerns, the talking points used, and the predictions of what the future holds in a post-reform world differ greatly between the two sides, but at the most basic level, everyone should agree that youth safety is important.

Arguably the most popular talking point for cannabis opponents is that, so they claim, if cannabis is legalized for adult use then there will be a spike in youth consumption at levels never seen before in human history, and the consequences of such will be nothing short of catastrophic.

Unfortunately for those opponents, and fortunately for the rest of us that live in reality, such spikes in youth consumption have yet to materialize where cannabis has been legalized. Furthermore, in Canada specifically, there have been fewer recorded incidents between youth and law enforcement following national legalization. Below is more information about it via a news release from NORML:

Toronto, Canada: The legalization of the adult-use marijuana market is associated with reduced incidents between police and juveniles, according to data published in the journal Drug and Alcohol Dependence.

Researchers affiliated with the Centre for Addiction and Mental Health in Toronto analyzed police-reported incident data from the years immediately prior to and following the adoption of cannabis legalization in Canada.

They reported that legalization “was associated with significant reductions in both male and female police-reported cannabis-related offenses” for youth ages 12 to 17. (Canadian law permits those age 18 and older to legally possess and use cannabis products.) They estimated that these reductions have led to approximately 21,000 fewer criminal interactions between police and young people in the years following nationwide legalization.

The study’s authors concluded: “The Cannabis Act was associated with sustained and substantial decreases of approximately 50 percent to 60 percent in national patterns of male and female police-reported youth cannabis-related criminal incidents over an approximate three-year post-legalization period.… Given that involvement with the police and Canadian criminal justice system for cannabis-related criminal incidents represents a major social and individual-level harm for young people, it is reasonable to conclude that our findings demonstrate a benefit associated with the implementation of the Cannabis Act.”

Full text of the study, “Canada’s cannabis legalization and police-reported cannabis-related criminal incidents among youth, 2015-2020,” appears in Drug and Alcohol Dependence.

The Global Rise Of Medical Cannabis

The legal medical cannabis industry is a global powerhouse now, however, that was obviously not always the case. International economists estimate that the legal medical cannabis market topped $31.8 billion USD in 2022 and that by 2030 the market size could more than double.

Yet, the emerging legal medical cannabis industry comes from fairly humble beginnings going back to the mid-1990s in California. A coalition of dedicated activists succeeded in getting the first medical cannabis legalization measure passed in California in 1996 and that victory set off a chain reaction that is still sweeping the globe today.

As medical cannabis reform has spread across the planet over the better part of the last three decades, the industry itself has evolved considerably during the same time period. The young legal industry in California in the mid-1990s doesn’t resemble the medical cannabis industry in existence today, including within California’s own borders.

The modern medical cannabis industry is far more sophisticated now compared to decades past, and rules and regulations are far more complex. With the rise of legal medical cannabis imports and exports, the complexities will likely only increase going forward.

Furthermore, adult-use reform is on the move, particularly in Europe where Germany is on the cusp of passing a national adult-use legalization measure. The modernization of adult-use cannabis policies will no doubt have an impact on medical cannabis policies in the regions where adult-use reform occurs.

All of that can make it hard to get a grasp on trends and opportunities, and it’s even harder when the industry and policy landscape shifts, which seems to be a frequent thing these days. Fortunately, there’s an opportunity to learn directly from leading international cannabis experts at the upcoming International Cannabis Business Conference in Berlin on June 29th-30th.

One of the panels for the conference, which is the largest and longest-running event of its type in Europe, is dedicated to discussing the rise of the global medical cannabis industry, and what impact legalization in Germany will have on the sector.

Georgia Glick, Head of Partnerships for Hanway Associates, will serve as the moderator of ‘The Global Rise of Medical Cannabis’ panel in Berlin. Joining Georgia Glick will be Lily Temperton, Head of Analysis for Hanway Associates, Lisa Haag, Founder of MJ_Universe, Alex Revich, Equity Partner at Hybrid Pharm and Cannabis Education & Medical Partnerships at Loosh Brands, Fleta Solomon, CEO of Little Green Pharma, and Dr. Malgorzata Meunier, CSO of Hapa Pharm.

Germany has emerged as a key player in the global medical cannabis market, with a robust regulatory framework and a growing number of patients accessing cannabis for therapeutic use. Although, Germany is not alone in its pursuit of medical cannabis.

Around the world, countries are exploring the potential of cannabis to treat a range of conditions, from chronic pain to epilepsy to cancer. In this panel, experts from Germany and beyond will take a closer look at the role of Germany in the international medical cannabis industry and explore emerging markets and pilot programs around the planet.

The panel will also discuss the critical importance of education for healthcare professionals, patients, and policymakers to ensure the safe and effective use of medical cannabis. You can view the full schedule for the upcoming International Cannabis Business Conference in Berlin at this link here.

Over 5,000 cannabis leaders from over 80 countries will be represented at the International Cannabis Business Conference in Berlin and that includes representatives from every sector of the industry as well as leading international cannabis policymakers and industry service providers.

Attend the International Cannabis Business Conference in Berlin to network with investors, entrepreneurs, industry regulators, and international policymakers and take your industry pursuits to the next level. Secure tickets now before the event is sold out!

Hemp Leaves No Longer A Novel Food Under EU Law

Cannabinoid-based products are increasing in popularity across the globe, and particularly so in Europe. ‘Cannabis light’ products are widely available in Europe, although they are not always completely legal.

Part of the problem is the patchwork of laws, rules, and regulations in Europe, with individual countries often having their own set of policies, with the European Union having sometimes conflicting policies. What is legal in one country may not be legal in another country, and all of it may be illegal in the eyes of the European Union depending on the situation.

To further complicate things, hemp and cannabis are treated differently by the governments of Europe (and elsewhere on earth), even though they are ultimately the same plant. If the THC content of a plant is under a threshold, typically .3-1%, then it is hemp. If it is above the threshold, then it is cannabis according to various governments.

It may seem like a big game of semantics to some, however, when it comes to public policy in Europe and the emerging industries that are governed by such policies, words matter. Thankfully, there is now reportedly clarification for hemp leaves at the European Union level, with the EU recently indicating that hemp leaves are no longer considered to be a ‘Novel Food.’ Per Cannabis Health News:

Hemp leaves, when separate from the flower, are now no longer classed as a Novel Food under EU law, permitting the sale of hemp-infused tea and tea-like products in member states.

An agreement to modify the Novel Food Catalogue was reached by EU members as part of a European Commission (EC) working group on Friday 2 June.

It’s now over four years since the EC made the controversial decision to classify all parts of the plants as Novel, meaning companies would need to apply for Novel Food status in order to legally sell cannabinoid-based products containing less than 0.3% THC in the EU.

The recent decision is obviously significant for people that sell cannabis teas and other products derived from hemp leaves. However, the decision clearly does not go far enough, and anything that is not derived from hemp leaves still faces a considerable amount of bureaucratic hurdles.

Europe’s emerging cannabis industry is increasing in size despite the playing field being far from level for cannabis companies compared to companies in many other major industries. Hopefully the governments of Europe, and the European Union itself, moves faster to modernize the continent’s cannabis policies.

Cannabis Associated With Lower Risk Of Fatty Liver Disease Per China Analysis

The dangers of fatty liver disease may not be well known around the globe, however, it’s a serious health condition. International researchers estimate that nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%.

Fatty liver disease involves an increased build-up of fat in the liver, and in extreme cases, it can result in liver failure. Symptoms of fatty liver disease include fatigue, weight loss, and abdominal pain.

Researchers in China recently explored the relationship between cannabis use and fatty liver disease, and the results of the analysis are significant. Below is more information about it via a news release from NORML:

Hubei, China: Adults with a history of cannabis use are less likely than non-users to be diagnosed with liver steatosis (abnormal fat retention a/k/a fatty liver disease), according to data published in the journal PLOS One.

A group of Chinese investigators assessed the relationship between marijuana use and the prevalence of fatty liver disease in a cohort of 2,622 US adults. Study participants consisted of current cannabis consumers, former consumers, and lifetime non-users.

Researchers determined that both current and former users possessed lower rates of liver steatosis than did those with no history of marijuana use – a finding that is consistent with numerous other studies.

Authors of the study concluded: “In this nationally representative sample, current marijuana use is inversely associated with steatosis. … Further studies are required to confirm these results longitudinally, and investigations into marijuana compounds and their biological effects are promising for treating and preventing fatty liver disease.”

The results of a 2018 meta-analysis, which reviewed nine studies involving nearly six million subjects, similarly acknowledged “a reduction in the prevalence of NAFLD (non-alcoholic fatty liver disease) in marijuana users.”

Full text of the study, “Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in the NHANES 2017-2018: A cross-sectional study,” appears in PLOS One.

Cannabis Associated With Sustained Benefits In Tourette Syndrome Patients

International health experts estimate that roughly 0.5-1% of the world’s population is diagnosed with some level of Tourette Syndrome, although the true diagnosis rate of people suffering from the condition could be larger due to gaps in identification and treatment in some parts of the globe.

According to the National Institute of Neurological Disorders and Stroke, “Tourette Syndrome (TS) is a neurological disorder characterized by sudden, repetitive, rapid, and unwanted movements or vocal sounds called tics.” Currently, there is no cure for the condition.

Various treatments for Tourette Syndrome exist, with common ones being dopamine blockers, Botox injections, ADHD medications, anti-depressants, and anti-seizure medications. All of those treatments can yield possible undesirable side effects. Fortunately, a recent study in Israel found that cannabis may help. Below is more information about it via a news release from NORML:

Tel Aviv, Israel: Patients with Tourette syndrome (TS) report that cannabis inhalation is associated with sustained improvements in their symptoms, according to data published in the journal Cannabis and Cannabinoid Research.

Israeli researchers assessed the long-term use of cannabis in 25 patients suffering from Gilles de la Tourette Syndrome. On average, patients in the study consumed cannabis for a period of four years, with some participants having used cannabis for up to nine years.

Patients reported sustained benefits in the management of TS and other comorbidities. Most subjects gradually increased their daily THC intake over time.

“Patients using MC [medical cannabis] reported an average 75 percent tic reduction compared with baseline,” authors determined. “A significant effect on comorbid conditions was [also] noted,” with 92 percent of subjects reporting reduced restlessness, 88 percent reporting improved mood, 84 percent reporting better sleep, and 75 percent reporting reduced anxiety.”

Authors concluded: “A subset of people with GTS report long-term significant benefit from continuous MC use with no disturbing side effects; however, they required escalating doses of THC over the years. Additional studies are required to test for objective improvement and for biological reasons that may explain dose escalation.”

Separate data published earlier this year reported that TS patients exhibit short-term improvements in their health-related quality of life as well as reductions in their use of prescription medications following cannabis treatment

Full text of the study, “Licensed medical cannabis use in Gilles de la Tourette syndrome: A retrospective long-term follow-up,” appears in Cannabis and Cannabinoid ResearchAdditional information on cannabinoids and TS is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

CBD Lowers Blood Pressure In Croatian Patients With Hypertension

Hypertension occurs when someone’s blood pressure is too elevated, typically above 140/90. The condition is considered severe if the pressure is above 180/120.  If left untreated, hypertension can cause serious health conditions, including heart disease and stroke.

International health experts estimate that roughly 30% of the planet’s adult human population suffers from hypertension to some degree, which works out to over one billion people globally.

Fortunately, the cannabis plant may be able to help, as evidenced by the results of a new study out of Croatia which examined the use of oral CBD and how it affects hypertension patients. Below is more information about the new study via a news release from NORML:

Split, Croatia: The oral administration of a proprietary encapsulated dose of CBD reduces ambulatory blood pressure in subjects suffering from either mild or moderate hypertension, according to placebo-controlled clinical trial data published in the journal Cannabis and Cannabinoid Research.

Researchers assessed the efficacy of CBD versus placebo in a cohort of 70 patients. Subjects received daily doses of either CBD or a placebo for five weeks. Patients consumed between 225 mgs and 450 mgs of CBD per day.

“The administration of CBD reduced average 24-hour mean, systolic, and diastolic BP [blood pressure] after 2.5 weeks,” investigators concluded. “There were no changes in liver enzymes of serious adverse events.”

Authors concluded: “The results of the present randomized, triple-blind, crossover study indicate that chronic administration of CBD [capsules] reduces ambulatory BP. … These findings should be confirmed in larger prospective cohorts to apply them into clinical practice.”

The trial’s findings are consistent with those of a 2017 British study finding that the administration of a single oral dose of 600 mgs of CBD reduced blood pressure in healthy volunteers. Another study reported that CBD dosing was associated with sustained lower levels of stress-induced high blood pressure

Israeli data has shown that the use of whole-plant cannabis also modulates blood pressure control. Authors of a 2021 study of elderly hypertension subjects determined, “Cannabis treatment for three months was associated with a reduction in systolic and diastolic blood pressure, as well as heart rate.” More recently, an analysis in the journal Nature: Scientific Reports concluded that current and lifetime cannabis use is associated with lower blood pressure levels in men and women.

Full text of the study, “Chronic effects of oral cannabidiol delivery on 24-h ambulatory blood pressure in patients with hypertension: A randomized, placebo-controlled, and cross-over study,” appears in Cannabis and Cannabinoid Research. Additional information on cannabinoids and blood pressure regulation is available from NORML’s publicationClinical Applications for Cannabis and Cannabinoids.

German Health Minister Sees Legalization’s Success In Canada Firsthand

Arguably the most popular person in the international cannabis scene right now, for better or worse, is German Health Minister Karl Lauterbach. Minister Lauterbach made international headlines in October 2022 when he presented a plan to Germany’s federal cabinet and has served as a primary focus of international cannabis observers like myself ever since.

For several months cannabis advocates watched Minister Lauterbach’s social media channels with a very close eye, and even some of his in-person appearances yielded speculation as to what it may mean for Germany’s legalization efforts. Now that Minister Lauterbach’s legalization plan is being circulated amongst lawmakers in Germany, the focus on him has lessened, however, it has not completely subsided.

That was on full display when Minister Lauterbach traveled days ago to Canada and met with Canada’s Minister for Mental Health and Addiction Dr. Bennett to discuss cannabis policy. What Minister Lauterbach witnessed with his own two eyes, legalization succeeding, was significant. Below is his tweet about it:

Auto-translating his tweet from German to English, the tweet stated: “Meeting today with Canadian Minister for Mental Health and Addiction Dr. Bennett on cannabis legalization. The doctor says legalization has not led to an increase in consumption there, not even among young people. 70% of the black market is gone.”

A lot of anti-cannabis rhetoric is being tossed around these days in Germany as the legalization push continues, and one of my biggest pet peeves is cannabis opponents acting as if Canada didn’t legalize cannabis for adult use at the national level in 2018, and that there is not a significant amount of data available as a result. Unfortunately for those opponents, the reality we all live in speaks for itself.

As Minister Lauterbach’s tweet points out, claims that cannabis consumption will spike post-legalization have not materialized in Canada, and it’s likely that any limited increase in reported use is more indicative of longtime consumers finally being willing to admit it to government data collectors.

Furthermore, youth consumption, which cannabis opponents seem to constantly try to make the focus of their fear-mongering propaganda efforts. has not increased post-legalization in Canada, and that’s per Canada’s Minister for Mental Health and Addiction.

Cannabis opponents will cling to the out-of-context talking point that the unregulated market still exists in Canada, however, knowing that 70% of cannabis sales have transitioned to the regulated market is obviously meaningful. That’s a massive amount of revenue that used to go to organized crime and now goes toward boosting Canada’s economy, including to funding projects that benefit non-cannabis consumers.

Legalization works. It is working in Canada, and it will also work in Germany and wherever else lawmakers modernize their jurisdiction’s cannabis policies in a sensible way.

Cannabis Opponents Spread Misinformation In Slovenia

Earlier this month cannabis opponents in Slovenia provided an open letter to European Commissioner for Home Affairs Ylva Johansson. The cannabis opponents also issued a press release, which is common for anti-cannabis propaganda efforts. The letter was sent by Preventivna Platforma, which describes itself as ‘a network of NGOs that work in the field of prevention.’ The entity’s professed overall goal is ‘quality in prevention’ and they tout in their publications that their efforts ‘receive financial assistance from Slovenia’s Ministry of Health.’

Preventivna Platforma’s letter was geared towards encouraging Commissioner Johansson to join them in opposing adult-use legalization in Germany. To someone that is not familiar with prohibitionist talking points, the letter may seem scary. However, as any long-time cannabis advocate will quickly point out, the letter is riddled with half-truths, lack of context, and in some cases, claims that are not supported by evidence and reality.

“As non-governmental organizations that work in the field of prevention, treatment, rehabilitation and recovery from drug use and addiction, we strongly oppose the legalization of cannabis. We are convinced that it will increase cannabis use and harm in Germany, and will also undermine the efforts of other EU member states in the field of preventing drug use and related harm.” the letter stated (translated from Slovenian to English.

As is often the case with anti-cannabis propaganda, the letter from Preventivna Platforma makes general claims that are easily refuted with peer-reviewed studies, logical reasoning, and government data from legal jurisdictions. For many years, opponents could make such claims and never be challenged because, after all, there were no legal jurisdictions to point to. That is obviously no longer the case.

We now know what happens when jurisdictions legalize cannabis for adult use; that the sky does not fall, and that the success of legalization in legal jurisdictions is likely why Preventivna Platforma relied so heavily on technical legal arguments in their letter rather than making a case that cannabis prohibition is better public policy than modernized regulation.

“Plans to legalize cannabis in Germany run counter to international drug control conventions, which have been ratified by all EU member states, among others. The International Narcotics Control Board (INCB) has repeatedly criticized similar policies in the United States, Canada and Uruguay.” Preventivna Platforma stated in its letter.

“By legalizing cannabis, Germany would also violate the sixth chapter of the Schengen Agreement, which stipulates that EU member states must respect the UN conventions on the control of illegal drugs and take the necessary measures to prevent illegal traffic in them. In addition, the German plans conflict with the EU Council Framework Decision 2004/757/RIF, which states that EU member states must ensure that the production, acquisition, sale, distribution, marketing, transportation and importation of illicit drugs, including cannabis, a felony.” the letter goes on to say.

Preventivna Platforma states in its letter that, “the German government wants to open up a legal, commercial market for cannabis, something that has not yet happened in any EU member state.” Obviously, there are two countries that have already legalized a cannabis commercial market at a national level, albeit not in Europe, and Preventivna Platforma omitting that fact seems to be purposeful. Cannabis opponents will always try to deflect and distract from legalization succeeding in other places.

A classic cannabis prohibitionist talking point that was incorporated by Preventivna Platforma in its letter ironically makes a strong argument for widespread legalization, which is the only true way to prevent diversion from regulated markets to unregulated markets.

“Undoubtedly, the legalization of cannabis in Germany would have a significant impact at least on neighboring countries. In a single market with open borders, it would be difficult to ensure that hemp grown legally in Germany does not divert to more profitable markets in other countries. Indeed, experience from the United States of America confirms that there is a high risk of diversion of cannabis from legal to illegal markets in other areas where its sale is not allowed.” the open letter states.

The letter goes on to cherry-pick certain information while ignoring other available information that either directly refutes their claims or puts it into proper context.

“After a decade, the legalization of cannabis in the countries where it has been legalized so far is still relatively in its infancy, but the first findings worry us. Data from the US show that cannabis consumption has increased, particularly more intensive use. Canadian data is scarcer, but official statistics show that both regular and frequent cannabis users have increased in the years since legalization.” Preventivna Platforma stated.

For starters, adults consuming more cannabis is not automatically a bad thing, and studies are showing that cannabis is often used as a substitute for more harmful substances, which is clearly a great thing. There seems to never be controls in the collection process of government usage data to calculate for long-time cannabis consumers finally admitting to government data collectors that they consume cannabis.

Government data collectors will record those people as being ‘new users’ when that is not actually the case. Speaking from firsthand experience, there was no way that I was ever going to tell the government that I consumed a product that was prohibited, and it’s logical to assume that I am far from alone in changing my answer after my jurisdiction’s (Oregon) cannabis policies were modernized. People need to keep that in mind when there are ‘rising consumption rates’ reported post-legalization.

Furthermore, and the propaganda letter tries to make it seem as if the two are connected, while adult use may be increasing in legal jurisdictions, the same is not true for kids and young people. It’s a ‘three card monte’ maneuver that prohibitions use because they assume that most people won’t unpack their talking points and that people will assume that if consumption rates are going up, then clearly that extends to young people. But as we know from data out of Canada, which is not ‘scarcer’ despite what prohibitionists claim, as well as data out of the United States, a spike in youth consumption post-legalization has yet to materialize.

Per government data from the Oregon Health Authority, not only was there no spike in youth consumption following the launch of legal adult-use sales and outright possession legalization in 2015; youth consumption rates actually went down from 2012 to 2018 in Oregon. A broader study conducted by researchers at Michigan State University, which involved consumption survey data from over 800,000 respondents in states where cannabis sales were permitted, also found no spike in youth cannabis usage rates.

A study in 2021 conducted by researchers in Canada found ‘no significant differences’ in cannabis consumption rates before and after cannabis legalization in Canada. As of May 2022, data out of Uruguay also demonstrated no sustained changes in youth consumption rates post-legalization.

Another popular prohibitionist talking point that does not provide nearly enough context is that ‘the unregulated cannabis market still exists in Canada and the United States.’

“One of the main goals of legalization was to eliminate the illegal cannabis market. However, there is still a thriving illegal market in all jurisdictions, supplying both the local market and markets in neighboring countries.” Preventivna Platforma stated.

Make no mistake about it, the unregulated cannabis market will always exist, just as the unregulated tobacco and alcohol markets will always exist, and the market for fake apparel and bootlegged entertainment media will always exist. Just because an unregulated market exists to some small degree does not in any way justify prohibition and the economic and social costs that go with it. The goal is to mitigate the unregulated market as much as reasonably possible for various reasons, not the least of which are improving public health outcomes via boosting regulated product availability, and taking money out of the hands of organized crime.

One talking point that is seemingly always included in anti-cannabis propaganda is the ‘terror on the roadways’ talking point.

“The increase in use is accompanied, among other things, by an increase in the number of traffic accidents and accompanying deaths related to cannabis, an increase in the number of visits to emergency centers and hospitalizations…” the letter stated.

However, a study from this month out of Canada found that, per the researchers, “[N]either the CCA [Canadian Cannabis Act] nor the NCS [number of cannabis stores per capita] is associated with concomitant changes in (traffic safety) outcomes. … During the first year of the CRUL’s [cannabis recreational use laws] implementation in Toronto, no significant changes in crashes, number of road victims and KSI [all road users killed or severely injured] were observed.”

The Preventivna Platforma letter goes on to indicate that there is still a lot that is “unknown” when it comes to legalization and that the “consequences” of cannabis hyperemesis syndrome (CHS), which is an extremely rare condition, were “not known until a few years ago.” That claim was made despite the condition being mentioned in a study nearly twenty years ago.

Also, a study from this month out of the legal state of Massachusetts in the U.S. found that CHS only represented .1% of all hospitalizations in 2021. It’s a serious thing that sufferers need to be mindful of, however, it’s far from being an epidemic and the most common treatment for CHS is a warm shower and refraining from consuming cannabis. Furthermore, it’s entirely possible that the current rates for CHS in legal jurisdictions were always what is being reported now, but that people were too afraid to seek out medical advice pre-legalization due to fear of prosecution.

One citation that stood out to me in the letter was applied to the claim that THC vaping is responsible for “an epidemic of serious lung disease.” However, upon further examination, the citation is from the United States Centers for Disease Control’s (CDC) tobacco overview page. The CDC points out on that page that it is not regulated products that are responsible for suspected lung issues, but rather, the unregulated market, and it is classified as an “outbreak” and not an “epidemic.”

“National and state data from patient reports and product sample testing show tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, products, particularly from informal sources like friends, family, or in-person or online dealers, are linked to most EVALI cases and play a major role in the outbreak.” the CDC states on the page that is cited in the Slovenian anti-cannabis propaganda letter.

“Vitamin E acetate is strongly linked to the EVALI outbreak. Vitamin E acetate has been found in product samples tested by FDA and state laboratories and in patient lung fluid samples tested by CDC from geographically diverse states. Vitamin E acetate has not been found in the lung fluid of people that do not have EVALI.” the page goes on to say, which directly refutes the claim in the propaganda letter that THC from regulated products is the culprit for issues.

Again, the cannabis prohibitionists responsible for the recent letter make no genuine effort to argue that cannabis prohibition is an effective policy. Rather, they offer up half-truths, lack of context, and in some cases outright inaccurate information. Much like cannabis prohibitionists found elsewhere in the world, such as Kevin Sabet, they do anything they can to slow down the modernization of cannabis policies because, presumably, they know that the status quo is on their side, and they don’t have to move any needles.

All cannabis opponents must do is muck up the process and try to confuse as many people as possible, and they know it. They presumably believe that doing so will prevent meaningful reform from occurring, and that comes at the expense of having a rational conversation about cannabis policy in Slovenia, Europe, and anywhere else where these types of cannabis propaganda spreaders operate. Hopefully the citizens of Slovenia and European Commissioner for Home Affairs Ylva Johansson will see through the propaganda, and support Slovenia modernizing its cannabis policies for the sake of improved public health outcomes, as well as for the increased economic opportunities that sensible cannabis policies create.

Medical Cannabis Pilot Project Proposed In Iceland

The concept of cannabis commerce pilot projects is not a new thing and is seemingly growing in popularity among policymakers and regulators in Europe. The latest example of that can be found in Iceland, where a proposal was recently submitted to launch a medical cannabis-focused pilot project.

For those that may be unfamiliar with cannabis commerce pilot projects, medical and adult-use cannabis commerce projects allow jurisdictions to permit limited, legal cannabis commerce. The theory behind the concept is that it affords policymakers and regulators the opportunity to see how commerce works on a limited scale to be better suited to craft national policies.

Denmark currently has a medical-focused pilot program, and adult-use pilot programs are popping up in Switzerland. According to the current legalization plan in Germany, pilot programs will be part of the second phase of legalization once the details are figured out.

Iceland’s pilot project is somewhat different than what is going on in Switzerland, and eventually Germany, beyond just Iceland’s proposal being for medical versus adult use. One could easily argue that the proposal in Iceland is essentially an expansion of the nation’s medical cannabis program, albeit in a limited-duration fashion. Per Cannabis Health News:

Following a debate in Alþingi [Icelandic parliament] last week, officials have proposed a four-year pilot project to permit the use of medical cannabis, as well as the cultivation, production and distribution of cannabis-based products for medicinal use.

If approved, the Ministry of Health will work with the Minister of Culture and Trade to establish a working group to prepare a bill allowing companies to apply for licences to produce and distribute cannabis medicines.

The bill would need to be presented by the ministry by 31st December with the four-year pilot programme expected to begin on 1 January, 2024.

Currently, only the pharmaceutical product Sativex is available to suffering patients in Iceland, and even then, only in limited circumstances. Just as is the case everywhere around the globe, suffering patients in Iceland deserve to have safe, legal access to their medicine in whatever form helps them the best.

Only time will tell if the proposal in Iceland makes it to the finish line this year, and even if it does, whether or not 2024 will end up being the actual launch year. Pilot projects are notorious for experiencing delayed implementations. Hopefully that doesn’t prove to be the case in Iceland.